doi: 10.1001/jamapsychiatry.2025.2332 12 GaoS
Treatment duration varies by individual
Jayne Hornung, chief clinical officer at Managed Markets Insight and Technology, suggests initial pricing of oral GLP-1s for weight loss could be reminiscent of the early days of anti-CGRP medications for migraines when the first oral CGRP came to market in 2019, the pricing still remained high
It should not be chewed or crushed
However, a high-fat diet and subsequent development of NASH can downregulate hepatic GLP-1R expression, thereby inducing therapeutic resistance to this medication in certain patients (Svegliati-Baroni et al., 2011
Unless theres a specific short-term indication (recent stent, acute event), its time to go monotherapy